NCT02478645View on ClinicalTrials.gov

Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

June 19, 2015

Primary Completion Date

February 6, 2016

Study Completion Date

February 6, 2016

Conditions
Postoperative Nausea and Vomiting
Interventions
DRUG

ramosetron 0.3

The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.

DRUG

ramosetron 0.45

The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.

DRUG

ramosetron 0.6

The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.

Trial Locations (1)

120-752

Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02478645 - Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery | Biotech Hunter | Biotech Hunter